NHS NEL
Demonstration Formulary
Demonstration Formulary
3 Respiratory system
03-04-02 Omalizumab
| Omalizumab Xolair® |
|
Restricted
|
For specialist use only in line with NICE TAs |
 NICE TA 339: Omalizumab for previously treated chronic spontaneous urticaria TA278 Asthma (severe, persistent, patients aged 6+,adults) - omalizumab (revised TA133, TA201) |
|
Links
BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old - BCICB Asthma Treatment Guidelines - Adults 18+
- BCICB Asthma Treatment Guidelines For Children Under 12
- BCICB COPD Inhaler Treatment Guidelines
- BCICB Difficult Asthma Referral Pathway - Adults 18+
- COVID-19: information for the respiratory community
- Greener Inhaler Guide Switching Information
- How to improve respiratory control in asthma and COPD
- NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE TA 339: Omalizumab for previously treated chronic spontaneous urticaria
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
- NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
- NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA479: Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA769: Palforzia for treating peanut allergy in children and young people
- TA278 Asthma (severe, persistent, patients aged 6+,adults) - omalizumab (revised TA133, TA201)